Antiphospholipid Antibodies Modify the Prognostic Value of Baseline Platelet Count for Clinical Outcomes After Ischemic Stroke
Antiphospholipid antibodies (aPLs) have been reported to be involved in platelet-mediated thrombosis and inflammation, but the impact on the prognosis of ischemic stroke remains unclear. We aimed to examine whether the association between baseline platelet count (PLT) and long-term clinical outcomes...
Saved in:
Published in | Journal of the American Heart Association Vol. 13; no. 19; p. e035183 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
John Wiley and Sons Inc
01.10.2024
Wiley |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Antiphospholipid antibodies (aPLs) have been reported to be involved in platelet-mediated thrombosis and inflammation, but the impact on the prognosis of ischemic stroke remains unclear. We aimed to examine whether the association between baseline platelet count (PLT) and long-term clinical outcomes within 2 years after ischemic stroke onset is modulated by aPLs.
A total of 2938 patients with ischemic stroke were included in this prospective cohort study. Cox proportional hazards regression models were used to assess the association between the baseline PLT stratified by aPLs status and 2-year clinical outcomes after stroke onset, and an interaction effect between PLT and aPLs on clinical outcomes was tested by likelihood ratio test. There was a significant interaction effect of aPLs and PLT on recurrent stroke (
=0.002) and cardiovascular events (
=0.001) within 2 years after stroke onset. After multivariate adjustment, high PLT was associated with increased risks of recurrent stroke (hazard ratio [HR], 2.78 [95% CI, 1.03-7.45];
=0.039) and cardiovascular events (HR, 2.58 [95% CI, 1.12-5.90];
=0.024) when 2 extreme tertiles were compared among patients with aPL positive, but not among those with aPL negative.
The aPLs had a modifying effect on the association between PLT and clinical outcomes within 2 years after ischemic stroke onset. Increased PLT was associated with recurrent stroke and cardiovascular events after ischemic stroke onset among patients with aPL positive, but not in those with aPL negative. |
---|---|
AbstractList | Antiphospholipid antibodies (aPLs) have been reported to be involved in platelet-mediated thrombosis and inflammation, but the impact on the prognosis of ischemic stroke remains unclear. We aimed to examine whether the association between baseline platelet count (PLT) and long-term clinical outcomes within 2 years after ischemic stroke onset is modulated by aPLs.
A total of 2938 patients with ischemic stroke were included in this prospective cohort study. Cox proportional hazards regression models were used to assess the association between the baseline PLT stratified by aPLs status and 2-year clinical outcomes after stroke onset, and an interaction effect between PLT and aPLs on clinical outcomes was tested by likelihood ratio test. There was a significant interaction effect of aPLs and PLT on recurrent stroke (
=0.002) and cardiovascular events (
=0.001) within 2 years after stroke onset. After multivariate adjustment, high PLT was associated with increased risks of recurrent stroke (hazard ratio [HR], 2.78 [95% CI, 1.03-7.45];
=0.039) and cardiovascular events (HR, 2.58 [95% CI, 1.12-5.90];
=0.024) when 2 extreme tertiles were compared among patients with aPL positive, but not among those with aPL negative.
The aPLs had a modifying effect on the association between PLT and clinical outcomes within 2 years after ischemic stroke onset. Increased PLT was associated with recurrent stroke and cardiovascular events after ischemic stroke onset among patients with aPL positive, but not in those with aPL negative. Antiphospholipid antibodies (aPLs) have been reported to be involved in platelet-mediated thrombosis and inflammation, but the impact on the prognosis of ischemic stroke remains unclear. We aimed to examine whether the association between baseline platelet count (PLT) and long-term clinical outcomes within 2 years after ischemic stroke onset is modulated by aPLs.BACKGROUNDAntiphospholipid antibodies (aPLs) have been reported to be involved in platelet-mediated thrombosis and inflammation, but the impact on the prognosis of ischemic stroke remains unclear. We aimed to examine whether the association between baseline platelet count (PLT) and long-term clinical outcomes within 2 years after ischemic stroke onset is modulated by aPLs.A total of 2938 patients with ischemic stroke were included in this prospective cohort study. Cox proportional hazards regression models were used to assess the association between the baseline PLT stratified by aPLs status and 2-year clinical outcomes after stroke onset, and an interaction effect between PLT and aPLs on clinical outcomes was tested by likelihood ratio test. There was a significant interaction effect of aPLs and PLT on recurrent stroke (Pinteraction=0.002) and cardiovascular events (Pinteraction=0.001) within 2 years after stroke onset. After multivariate adjustment, high PLT was associated with increased risks of recurrent stroke (hazard ratio [HR], 2.78 [95% CI, 1.03-7.45]; Ptrend=0.039) and cardiovascular events (HR, 2.58 [95% CI, 1.12-5.90]; Ptrend=0.024) when 2 extreme tertiles were compared among patients with aPL positive, but not among those with aPL negative.METHODS AND RESULTSA total of 2938 patients with ischemic stroke were included in this prospective cohort study. Cox proportional hazards regression models were used to assess the association between the baseline PLT stratified by aPLs status and 2-year clinical outcomes after stroke onset, and an interaction effect between PLT and aPLs on clinical outcomes was tested by likelihood ratio test. There was a significant interaction effect of aPLs and PLT on recurrent stroke (Pinteraction=0.002) and cardiovascular events (Pinteraction=0.001) within 2 years after stroke onset. After multivariate adjustment, high PLT was associated with increased risks of recurrent stroke (hazard ratio [HR], 2.78 [95% CI, 1.03-7.45]; Ptrend=0.039) and cardiovascular events (HR, 2.58 [95% CI, 1.12-5.90]; Ptrend=0.024) when 2 extreme tertiles were compared among patients with aPL positive, but not among those with aPL negative.The aPLs had a modifying effect on the association between PLT and clinical outcomes within 2 years after ischemic stroke onset. Increased PLT was associated with recurrent stroke and cardiovascular events after ischemic stroke onset among patients with aPL positive, but not in those with aPL negative.CONCLUSIONSThe aPLs had a modifying effect on the association between PLT and clinical outcomes within 2 years after ischemic stroke onset. Increased PLT was associated with recurrent stroke and cardiovascular events after ischemic stroke onset among patients with aPL positive, but not in those with aPL negative. Background Antiphospholipid antibodies (aPLs) have been reported to be involved in platelet‐mediated thrombosis and inflammation, but the impact on the prognosis of ischemic stroke remains unclear. We aimed to examine whether the association between baseline platelet count (PLT) and long‐term clinical outcomes within 2 years after ischemic stroke onset is modulated by aPLs. Methods and Results A total of 2938 patients with ischemic stroke were included in this prospective cohort study. Cox proportional hazards regression models were used to assess the association between the baseline PLT stratified by aPLs status and 2‐year clinical outcomes after stroke onset, and an interaction effect between PLT and aPLs on clinical outcomes was tested by likelihood ratio test. There was a significant interaction effect of aPLs and PLT on recurrent stroke (Pinteraction=0.002) and cardiovascular events (Pinteraction=0.001) within 2 years after stroke onset. After multivariate adjustment, high PLT was associated with increased risks of recurrent stroke (hazard ratio [HR], 2.78 [95% CI, 1.03–7.45]; Ptrend=0.039) and cardiovascular events (HR, 2.58 [95% CI, 1.12–5.90]; Ptrend=0.024) when 2 extreme tertiles were compared among patients with aPL positive, but not among those with aPL negative. Conclusions The aPLs had a modifying effect on the association between PLT and clinical outcomes within 2 years after ischemic stroke onset. Increased PLT was associated with recurrent stroke and cardiovascular events after ischemic stroke onset among patients with aPL positive, but not in those with aPL negative. |
Author | Peng, Hao Wang, Aili Zhu, Zhengbao Wang, Yinan Yang, Pinni Xu, Tan Zhang, Yonghong Bu, Xiaoqing Xu, Qingyun He, Jiang Chen, Jing |
AuthorAffiliation | 5 Department of Medicine Tulane University School of Medicine New Orleans LA USA 2 Ningbo Municipal Center for Disease Control and Prevention Ningbo China 4 Department of Epidemiology, School of Public Health Chongqing Medical University Chongqing China 3 Department of Epidemiology Tulane University School of Public Health and Tropical Medicine New Orleans LA USA 1 Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non‐communicable Diseases Suzhou Medical College of Soochow University Suzhou China |
AuthorAffiliation_xml | – name: 1 Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non‐communicable Diseases Suzhou Medical College of Soochow University Suzhou China – name: 2 Ningbo Municipal Center for Disease Control and Prevention Ningbo China – name: 4 Department of Epidemiology, School of Public Health Chongqing Medical University Chongqing China – name: 5 Department of Medicine Tulane University School of Medicine New Orleans LA USA – name: 3 Department of Epidemiology Tulane University School of Public Health and Tropical Medicine New Orleans LA USA |
Author_xml | – sequence: 1 givenname: Yinan orcidid: 0000-0003-2967-6058 surname: Wang fullname: Wang, Yinan organization: Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non‐communicable Diseases Suzhou Medical College of Soochow University Suzhou China, Ningbo Municipal Center for Disease Control and Prevention Ningbo China – sequence: 2 givenname: Pinni orcidid: 0000-0001-7327-3294 surname: Yang fullname: Yang, Pinni organization: Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non‐communicable Diseases Suzhou Medical College of Soochow University Suzhou China – sequence: 3 givenname: Zhengbao orcidid: 0000-0001-5500-0014 surname: Zhu fullname: Zhu, Zhengbao organization: Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non‐communicable Diseases Suzhou Medical College of Soochow University Suzhou China, Department of Epidemiology Tulane University School of Public Health and Tropical Medicine New Orleans LA USA – sequence: 4 givenname: Hao orcidid: 0000-0001-6277-662X surname: Peng fullname: Peng, Hao organization: Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non‐communicable Diseases Suzhou Medical College of Soochow University Suzhou China – sequence: 5 givenname: Xiaoqing orcidid: 0009-0007-4581-0444 surname: Bu fullname: Bu, Xiaoqing organization: Department of Epidemiology, School of Public Health Chongqing Medical University Chongqing China – sequence: 6 givenname: Qingyun surname: Xu fullname: Xu, Qingyun organization: Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non‐communicable Diseases Suzhou Medical College of Soochow University Suzhou China – sequence: 7 givenname: Aili surname: Wang fullname: Wang, Aili organization: Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non‐communicable Diseases Suzhou Medical College of Soochow University Suzhou China – sequence: 8 givenname: Jing orcidid: 0000-0002-9035-9126 surname: Chen fullname: Chen, Jing organization: Department of Epidemiology Tulane University School of Public Health and Tropical Medicine New Orleans LA USA, Department of Medicine Tulane University School of Medicine New Orleans LA USA – sequence: 9 givenname: Tan surname: Xu fullname: Xu, Tan organization: Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non‐communicable Diseases Suzhou Medical College of Soochow University Suzhou China – sequence: 10 givenname: Yonghong orcidid: 0000-0001-6188-3490 surname: Zhang fullname: Zhang, Yonghong organization: Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non‐communicable Diseases Suzhou Medical College of Soochow University Suzhou China – sequence: 11 givenname: Jiang orcidid: 0000-0002-8286-9652 surname: He fullname: He, Jiang organization: Department of Epidemiology Tulane University School of Public Health and Tropical Medicine New Orleans LA USA, Department of Medicine Tulane University School of Medicine New Orleans LA USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39344638$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kstv1DAQhyNUREvpmRvykctu_U5yQmEFdFFRkXhcLduZ7Lo48dZ2kHrhb8fLtqhFwpI1o3l8P1szz6ujKUxQVS8JXhIiyfnH7qJbEsqXmAnSsCfVCcW8XrRtg48e-MfVWUrXuBxJaybaZ9UxaxnnkjUn1a9uym63Dalc73auR_uACb2DhD4VM9yivAX0OYbNFFJ2Fn3XfgYUBvRWJ_BuKkmvM3jIaBXmKaMhRLQqCWe1R1dztmEssG7IENE62S2MhfIlx_ADXlRPB-0TnN3Z0-rb-3dfVxeLy6sP61V3ubBc4rwAKlppmalBWMH7AQsJRnBhodWSid5iSg1hAHRg3BqrW0ZaTnDNqZGEYnZarQ_cPuhrtYtu1PFWBe3Un0CIG6Vj-ZwHBTU2tAcprTbcNtQYgQfMhWFFvW6awnpzYO1mM0JvYcpR-0fQx5nJbdUm_FRlaA3hdVsIr-8IMdzMkLIaXbLgvZ4gzEkxQsqjaY1lKX31UOyvyv0ES4E4FNgYUoowKOuyzi7stZ1XBO91idoviyrLog7LUvrO_-m7R_-v4zfJd8II |
CitedBy_id | crossref_primary_10_1016_j_vph_2025_107474 |
Cites_doi | 10.1111/j.1538-7836.2009.03446.x 10.1093/rheumatology/key340 10.1212/WNL.43.10.2069 10.1212/01.WNL.0000086809.46485.A1 10.3390/ijms22084200 10.1161/01.STR.20.7.864 10.1159/000048623 10.1161/01.CIR.0000154900.76284.F6 10.1515/cclm-2022-0317 10.1161/STROKEAHA.114.005380 10.1182/blood-2016-07-692673 10.1182/blood-2014-02-554980 10.1161/CIRCULATIONAHA.116.025250 10.1161/01.STR.0000087149.42294.8C 10.1002/cphy.c170049 10.1196/annals.1361.083 10.1212/WNL.51.3_Suppl_3.S9 10.1161/CIRCULATIONAHA.105.548495 10.1212/WNL.0000000000010105 10.1161/STR.0000000000000375 10.1016/j.jns.2016.01.044 10.1016/S1474-4422(21)00252-0 10.1111/j.1538-7836.2007.02310.x 10.1016/j.jaut.2022.102813 10.1161/01.STR.32.8.1701 10.1177/1076029614550820 10.1161/01.STR.24.1.35 10.1111/ijlh.12474 10.1161/STROKEAHA.116.013827 10.1212/WNL.48.1.91 10.1055/s-0028-1082267 10.1161/STROKEAHA.107.189063 10.1111/j.1538-7836.2006.01753.x 10.1160/TH03-10-0608 10.1007/978-3-319-19425-7 10.1016/j.blre.2020.100788 10.1007/s11926-014-0494-8 10.1378/chest.11-2302 10.1002/sim.4780080504 10.3389/fneur.2019.00370 10.1001/jama.2013.282543 10.1002/sim.2929 |
ContentType | Journal Article |
Copyright | 2024 The Author(s). Published on behalf of the American Heart Association, Inc., by Wiley. |
Copyright_xml | – notice: 2024 The Author(s). Published on behalf of the American Heart Association, Inc., by Wiley. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
DOI | 10.1161/JAHA.124.035183 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | aPLs Modify the Association Between PLT and Stroke Prognosis |
EISSN | 2047-9980 |
ExternalDocumentID | oai_doaj_org_article_e70b2de66cab4c82bb50f045b37e5788 PMC11681479 39344638 10_1161_JAHA_124_035183 |
Genre | Journal Article |
GroupedDBID | 0R~ 1OC 24P 53G 5VS 8-1 AAYXX AAZKR ACCMX ACGFO ACXQS ADBBV ADKYN ADRAZ ADZMN AEGXH AENEX AIAGR ALAGY ALMA_UNASSIGNED_HOLDINGS AOIJS AVUZU BAWUL BCNDV CITATION DIK EBS EJD EMOBN GODZA GROUPED_DOAJ GX1 H13 HYE KQ8 M48 M~E OK1 RAH RNS RPM CGR CUY CVF ECM EIF NPM RHF WIN 7X8 AAMMB AEFGJ AGXDD AIDQK AIDYY 5PM |
ID | FETCH-LOGICAL-c460t-e2596c3b7e5c54df056eb545ce9a635dc022b13ee2f34cbca9319410742b61203 |
IEDL.DBID | M48 |
ISSN | 2047-9980 |
IngestDate | Wed Aug 27 01:25:33 EDT 2025 Thu Aug 21 18:29:49 EDT 2025 Thu Jul 10 22:32:23 EDT 2025 Wed Feb 19 02:00:25 EST 2025 Tue Jul 01 03:15:45 EDT 2025 Thu Apr 24 23:05:21 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 19 |
Keywords | platelet count prognosis antiphospholipid antibodies ischemic stroke |
Language | English |
License | This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c460t-e2596c3b7e5c54df056eb545ce9a635dc022b13ee2f34cbca9319410742b61203 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 This manuscript was sent to Jose R. Romero, MD, Associate Editor, for review by expert referees, editorial decision, and final disposition. Supplemental Material is available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.124.035183 For Sources of Funding and Disclosures, see page 9. |
ORCID | 0009-0007-4581-0444 0000-0001-7327-3294 0000-0001-6188-3490 0000-0001-5500-0014 0000-0001-6277-662X 0000-0002-9035-9126 0000-0002-8286-9652 0000-0003-2967-6058 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1161/JAHA.124.035183 |
PMID | 39344638 |
PQID | 3111202706 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_e70b2de66cab4c82bb50f045b37e5788 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11681479 proquest_miscellaneous_3111202706 pubmed_primary_39344638 crossref_citationtrail_10_1161_JAHA_124_035183 crossref_primary_10_1161_JAHA_124_035183 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2024-10-01 |
PublicationDateYYYYMMDD | 2024-10-01 |
PublicationDate_xml | – month: 10 year: 2024 text: 2024-10-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Hoboken |
PublicationTitle | Journal of the American Heart Association |
PublicationTitleAlternate | J Am Heart Assoc |
PublicationYear | 2024 |
Publisher | John Wiley and Sons Inc Wiley |
Publisher_xml | – name: John Wiley and Sons Inc – name: Wiley |
References | e_1_3_2_26_2 e_1_3_2_27_2 e_1_3_2_28_2 e_1_3_2_29_2 e_1_3_2_41_2 e_1_3_2_40_2 e_1_3_2_20_2 e_1_3_2_43_2 e_1_3_2_21_2 e_1_3_2_42_2 e_1_3_2_22_2 e_1_3_2_23_2 e_1_3_2_24_2 e_1_3_2_25_2 e_1_3_2_9_2 e_1_3_2_15_2 e_1_3_2_38_2 e_1_3_2_8_2 e_1_3_2_16_2 e_1_3_2_37_2 e_1_3_2_7_2 e_1_3_2_17_2 e_1_3_2_6_2 e_1_3_2_18_2 e_1_3_2_39_2 e_1_3_2_19_2 e_1_3_2_30_2 e_1_3_2_32_2 e_1_3_2_10_2 e_1_3_2_31_2 e_1_3_2_5_2 e_1_3_2_11_2 e_1_3_2_34_2 e_1_3_2_4_2 e_1_3_2_12_2 e_1_3_2_33_2 e_1_3_2_3_2 e_1_3_2_13_2 e_1_3_2_36_2 e_1_3_2_2_2 e_1_3_2_14_2 e_1_3_2_35_2 |
References_xml | – ident: e_1_3_2_31_2 doi: 10.1111/j.1538-7836.2009.03446.x – ident: e_1_3_2_30_2 doi: 10.1093/rheumatology/key340 – ident: e_1_3_2_33_2 doi: 10.1212/WNL.43.10.2069 – ident: e_1_3_2_13_2 doi: 10.1212/01.WNL.0000086809.46485.A1 – ident: e_1_3_2_16_2 doi: 10.3390/ijms22084200 – ident: e_1_3_2_18_2 doi: 10.1161/01.STR.20.7.864 – ident: e_1_3_2_14_2 doi: 10.1159/000048623 – ident: e_1_3_2_19_2 doi: 10.1161/01.CIR.0000154900.76284.F6 – ident: e_1_3_2_24_2 doi: 10.1515/cclm-2022-0317 – ident: e_1_3_2_41_2 doi: 10.1161/STROKEAHA.114.005380 – ident: e_1_3_2_6_2 doi: 10.1182/blood-2016-07-692673 – ident: e_1_3_2_34_2 doi: 10.1182/blood-2014-02-554980 – ident: e_1_3_2_2_2 doi: 10.1161/CIRCULATIONAHA.116.025250 – ident: e_1_3_2_4_2 doi: 10.1161/01.STR.0000087149.42294.8C – ident: e_1_3_2_5_2 doi: 10.1002/cphy.c170049 – ident: e_1_3_2_38_2 doi: 10.1196/annals.1361.083 – ident: e_1_3_2_7_2 doi: 10.1212/WNL.51.3_Suppl_3.S9 – ident: e_1_3_2_11_2 doi: 10.1161/CIRCULATIONAHA.105.548495 – ident: e_1_3_2_43_2 doi: 10.1212/WNL.0000000000010105 – ident: e_1_3_2_40_2 doi: 10.1161/STR.0000000000000375 – ident: e_1_3_2_10_2 doi: 10.1016/j.jns.2016.01.044 – ident: e_1_3_2_3_2 doi: 10.1016/S1474-4422(21)00252-0 – ident: e_1_3_2_35_2 doi: 10.1111/j.1538-7836.2007.02310.x – ident: e_1_3_2_15_2 doi: 10.1016/j.jaut.2022.102813 – ident: e_1_3_2_32_2 doi: 10.1161/01.STR.32.8.1701 – ident: e_1_3_2_9_2 doi: 10.1177/1076029614550820 – ident: e_1_3_2_20_2 doi: 10.1161/01.STR.24.1.35 – ident: e_1_3_2_25_2 doi: 10.1111/ijlh.12474 – ident: e_1_3_2_12_2 doi: 10.1161/STROKEAHA.116.013827 – ident: e_1_3_2_42_2 doi: 10.1212/WNL.48.1.91 – ident: e_1_3_2_39_2 doi: 10.1055/s-0028-1082267 – ident: e_1_3_2_26_2 doi: 10.1161/STROKEAHA.107.189063 – ident: e_1_3_2_28_2 doi: 10.1111/j.1538-7836.2006.01753.x – ident: e_1_3_2_36_2 doi: 10.1160/TH03-10-0608 – ident: e_1_3_2_22_2 doi: 10.1007/978-3-319-19425-7 – ident: e_1_3_2_29_2 doi: 10.1016/j.blre.2020.100788 – ident: e_1_3_2_37_2 doi: 10.1007/s11926-014-0494-8 – ident: e_1_3_2_27_2 doi: 10.1378/chest.11-2302 – ident: e_1_3_2_21_2 doi: 10.1002/sim.4780080504 – ident: e_1_3_2_8_2 doi: 10.3389/fneur.2019.00370 – ident: e_1_3_2_17_2 doi: 10.1001/jama.2013.282543 – ident: e_1_3_2_23_2 doi: 10.1002/sim.2929 |
SSID | ssj0000627359 |
Score | 2.360803 |
Snippet | Antiphospholipid antibodies (aPLs) have been reported to be involved in platelet-mediated thrombosis and inflammation, but the impact on the prognosis of... Background Antiphospholipid antibodies (aPLs) have been reported to be involved in platelet‐mediated thrombosis and inflammation, but the impact on the... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | e035183 |
SubjectTerms | Aged Antibodies, Antiphospholipid - blood antiphospholipid antibodies Biomarkers - blood Blood Platelets - immunology Female Humans ischemic stroke Ischemic Stroke - blood Ischemic Stroke - diagnosis Ischemic Stroke - immunology Male Middle Aged Original Research Platelet Count Predictive Value of Tests Prognosis Prospective Studies Recurrence Risk Assessment Risk Factors Time Factors |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwELYqDlUviL5gW1oZqQcugSR2nOS4VEUL0rZILRU3y2OPxapRslqyBy78dsZJWO0iKi4cokjxI45nnPnGHn9m7JsqQKDJVKSsc5GU0kSFdybyMaTCQQLQUQpNf6rJpTy_yq7WjvoKMWE9PXDfcceYUymHSlkD0hYpQBZ7wiEgciRt67b5ks1bc6b6fzCZ5awcuHwI1Ryfjydh4k8ehaWzQmyYoY6t_ymI-ThScs30nO6w7QEz8nHf1rfsFdbv2OvpsCr-nt2N63Y2v25u6Kpm85nj4QE0IUCQT-nmbznhPH6xaEJYHdXC_5pqibzx_MR0O9IpsSLUSULkYZd6ywnL8oEztOK_li0pJlU2DieK8zPyiENMPf_dLpp_-IFdnv74830SDecqRFaquI2QXB5lBVAH2kw6TxgIgZCUxdIQ_nCW7DokAjH1QlqwpqRxKkPkZgoEiGLxkW3VTY17jAM4753yeW5LqSSWKWZl4UyBSWqlhBE7euhmbQfS8XD2RaU750MlOshFk1x0L5cRO1wVmPd8G__PehLktsoWiLK7B6Q-elAf_Zz6jNjBg9Q1DaywWmJqbJY3WpAVCDNDsRqx3V4LVq8SpSA3WlDpYkM_NtqymVLPrjvybvqSIpF5-eklWv-ZvaEmyj64cJ9ttYslfiGQ1MLXbjzcA_I4Edg priority: 102 providerName: Directory of Open Access Journals |
Title | Antiphospholipid Antibodies Modify the Prognostic Value of Baseline Platelet Count for Clinical Outcomes After Ischemic Stroke |
URI | https://www.ncbi.nlm.nih.gov/pubmed/39344638 https://www.proquest.com/docview/3111202706 https://pubmed.ncbi.nlm.nih.gov/PMC11681479 https://doaj.org/article/e70b2de66cab4c82bb50f045b37e5788 |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1Lb9QwELagSFUvqLxDHzISBy5ZkthxnANCW0S1VFpAgkW9RR4_2hVRsmSzEr3w2xkn2aWLtocokp-xZybz2R7PEPJaSGBWpSIU2piQc65C6YwKXQQJMxADdC6Fpp_FZMYvLtPLf-GAhglc7lza-XhSs6Yc_f518x4F_l0n8CJ-ezGe-D09PvKnYpLdJw9QLWU-nMF0wPr9bxk1dZoP7n121Dsg-yxnuDzyd1VuKanOl_8uAPq_HeUtxXR-SB4OiJKOexZ4RO7Z6jHZnw5n5k_In3HVzhfX9RKfcr6YG-oToPbmg3SKL3dDEQXSr03tje6wFfpDlStLa0fPVHdfHTNLxKRIYurvsLcUkS4dPIqW9MuqRbbFxsY-3jj9hJPqLe7pt7apf9qnZHb-8fuHSThEXQg1F1EbWlwQCc0gs6lOuXGIkCwgztI2V4hOjEatDzGzNnGMa9AqRynm3q4zAYRLEXtG9qq6si8IBTDOGeGyTOdccJsnNs2lUdLGieYcAjJaT3OhB5fkPjJGWXRLExEXnkQFkqjoSRSQN5sKi94bx91FzzzdNsW8G-0uoW6uikEqC5shSxorhFbAtUwA0sghyAWGo8-kDMirNdULFDt_lqIqW6-WBUMd4feNIhGQ5z0XbLpac1FA5BZ_bH3Ldk41v-5ce-NIZMyz_OWdjR6RA-yX9_aEx2SvbVb2BHFRC6fdfsJpx_V_AbaBDE8 |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antiphospholipid+Antibodies+Modify+the+Prognostic+Value+of+Baseline+Platelet+Count+for+Clinical+Outcomes+After+Ischemic+Stroke&rft.jtitle=Journal+of+the+American+Heart+Association&rft.au=Wang%2C+Yinan&rft.au=Yang%2C+Pinni&rft.au=Zhu%2C+Zhengbao&rft.au=Peng%2C+Hao&rft.date=2024-10-01&rft.eissn=2047-9980&rft.volume=13&rft.issue=19&rft.spage=e035183&rft_id=info:doi/10.1161%2FJAHA.124.035183&rft_id=info%3Apmid%2F39344638&rft.externalDocID=39344638 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2047-9980&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2047-9980&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2047-9980&client=summon |